InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.09 -0.82%

-$0.02 today

Market cap
$160.63M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 0.66M

Average 1.80M

Returns on capital

InflaRx N.V. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-109.9%

avg -34.0%

ROIC

-113.6%

avg -54.9%

ROA

-82.7%

avg -48.4%

Analysis

ROA is currently the strongest return metric at -82.7% versus its period average of -48.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Maria Habel

Vice President, Head of Preclinical R&D and QC—44——

Thomas Taapken

Chief Financial Officer—613.50K<0.01%

Christian Schmid

Vice President and Head of Legal Affairs & General Counsel————

Daniel Vetter

Senior Director & Head of IT————

Jan Medina

Head of Investor Relations & Vice President————

Kofi Boaten

VP and Head of Supply Quality & Clinical Trial Supplies————

Peter Hurt

Senior Director and Head of Drug Safety & Pharmacovigiliance————

Derval O'Carroll

Senior Vice President and Global Head of Regulatory Affairs & Compliance—6020.00K0.03%

Niels C. Riedemann

Co-Founder, Chief Executive Officer & Executive Director—53——

Renfeng Guo

Co-Founder, Chief Scientific Officer & Executive Director—565.41K<0.01%

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+216.8% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Forward estimates point to Revenue at +216.8% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does InflaRx N.V. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IFRX's management, answered from reported figures.

Who manages IFRX?

InflaRx N.V. (IFRX) lists 10 active executives. The top listed executive is Maria Habel, Vice President, Head of Preclinical R&D and QC.

Are IFRX insiders buying or selling?

Recent insider activity shows net buying of $0.00.